Unlabelled: Radiolabeled bombesin (BBN) analogs that bind to the gastrin-releasing peptide receptor (GRPR) represent a topic of active investigation for the development of molecular probes for PET or SPECT of prostate cancer (PCa). RM1 and AMBA have been identified as the 2 most promising BBN peptides for GRPR-targeted cancer imaging and therapy. In this study, to develop a clinically translatable BBN-based PET probe, we synthesized and evaluated (18)F-AlF- (aluminum-fluoride) and (64)Cu-radiolabeled RM1 and AMBA analogs for their potential application in PET imaging of PCa.
Methods: 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA)-conjugated RM1 and AMBA were synthesized and tested for their GRPR-binding affinities. The NODAGA-RM1 and NODAGA-AMBA probes were further radiolabeled with (64)Cu or (18)F-AlF and then evaluated in a subcutaneous PCa xenograft model (PC3) by small-animal PET imaging and biodistribution studies.
Results: NODAGA-RM1 and NODAGA-AMBA can be successfully synthesized and radiolabeled with (64)Cu and (18)F-AlF. (64)Cu- and (18)F-AlF-labeled NODAGA-RM1 demonstrated excellent serum stability and tumor-imaging properties in the in vitro stability assays and in vivo imaging studies. (64)Cu-NODAGA-RM1 exhibited tumor uptake values of 3.3 ± 0.38, 3.0 ± 0.76, and 3.5 ± 1.0 percentage injected dose per gram of tissue (%ID/g) at 0.5, 1.5, and 4 h after injection, respectively. (18)F-AlF-NODAGA-RM1 exhibited tumor uptake values of 4.6 ± 1.5, 4.0 ± 0.87, and 3.9 ± 0.48 %ID/g at 0.5, 1, and 2 h, respectively.
Conclusion: The high-stability, efficient tumor uptake and optimal pharmacokinetic properties highlight (18)F-AlF-NODAGA-RM1 as a probe with great potential and clinical application for the PET imaging of prostate cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215198 | PMC |
| http://dx.doi.org/10.2967/jnumed.113.121533 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.
Eur J Nucl Med Mol Imaging
January 2025
Departments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, WI, 53705, USA.
Purpose: Trophoblast cell-surface antigen 2 (Trop2) is overexpressed in various solid tumors and contributes to tumor progression, while its expression remains low in normal tissues. Trop2-targeting antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy in targeting this antigen. Leveraging the enhanced specificity of ADCs, we conducted the first immunoPET imaging study of Trop2 expression in gastric cancer (GC) and triple-negative breast cancer (TNBC) models using Zr-labeled Trodelvy ([Zr]Zr-DFO-Trodelvy).
View Article and Find Full Text PDFImpact of tissue-independent positron range correction on [Ga]Ga-DOTATOC and [Ga]Ga-PSMA PET image reconstructions: a patient data study.
Eur J Nucl Med Mol Imaging
January 2025
Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Purpose: The positron range effect can impair PET image quality of Gallium-68 (Ga). A positron range correction (PRC) can be applied to reduce this effect. In this study, the effect of a tissue-independent PRC for Ga was investigated on patient data.
View Article and Find Full Text PDFDevelopment of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography.
Eur J Nucl Med Mol Imaging
January 2025
Institute of Radiation Medicine, Fudan University, Xietu Road 2094, Shanghai, 200032, China.
Objectives: Mesothelin (MSLN) is an antigen that is overexpressed in various cancers, and its interaction with tumor-associated cancer antigen 125 plays a multifaceted role in tumor metastasis. The serum MSLN expression level can be detected using enzyme-linked immunosorbent assay; however, non-invasive visualization of its expression at the tumor site is currently lacking. Therefore, the aim of this study was to develop a molecular probe for imaging MSLN expression through positron emission tomography (PET).
View Article and Find Full Text PDFDiagnostic Feasibility of Cardiac PET CT in the Evaluation of Inflammatory, Infectious, and Malignant Heart Disease.
R I Med J (2013)
February 2025
Alpert Medical School of Brown University, Department of Medicine, Division of Cardiology, Rhode Island Hospital.
Cardiac Positron Emission Tomography (PET) is a power- ful imaging tool with diverse applications in the detection and diagnosis of various cardiac conditions, including inflammatory, infectious, and neoplastic processes. Using the radiotracer 18F-fluorodeoxyglucose (18F-FDG), cardiac PET enables the identification of cardiac involvement in diseases such as sarcoidosis and severe infections affecting the heart tissue. Additionally, 18F-FDG PET is valuable in the evaluation of cardiac masses, helping to assess their metabolic activity and potential malignancy.
View Article and Find Full Text PDFDiagnostic Feasibility and Accuracy of Cardiac Positron Emission Tomography (PET) in the Evaluation of Ischemic Heart Disease.
R I Med J (2013)
February 2025
Alpert Medical School of Brown University, Department of Medicine, Division of Cardiology, Rhode Island Hospital.
Cardiac Positron Emission Tomography (PET) can be used for the assessment of myocardial perfusion. Compared to other cardiac imaging techniques, notably Single Photon Emission Computer Tomography (SPECT), cardiac PET offers superior image resolution, higher accuracy, quantitative measures of myocardial perfusion, lower radiation exposure, and shorter image acquisition time. However, PET tends to be costlier and less widely available than SPECT due to the specialized equipment needed for generating the necessary radiotracers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!